Specific activity determination and stability studies of therapeutic 131I-mIBG radiopharmaceutical

Determination of Impurities and Degradation Products/Causes for <i>m</i>-Iodobenzylguanidine Using HPLC-Tandem Mass Spectrometry

“…m-Iodobenzylguanidine (MIBG, Figure 1) is structurally similar to the neurotransmitter norepinephrine (NE) and acts as an adrenergic neuron blocker. Therefore, it is easily absorbed by cells rich in sympathetic neurons, such as those of the heart and neuroendocrine glands, via an active uptake process regulated by the NE transporter (NET) which is responsible for shuttling NE into cells [1] [2] [3]. When MIBG is labeled with radioactive iodine ( 123/124/131 I-MIBG), it is employed as a radiopharmaceutical agent in pathology diagnosis of various neuroendocrine gland tumors, including neuroblastoma, paragonglioma, pheochromocytoma, malignant glioma, thyroid medullary carcinoma, malignant schwannoma, and myocardial imaging by single-photon emission computed tomography (SPECT) and positron emission tomography (PET).…”

The vial kit formulation for preparation of no‐carrier‐added 131I‐MIBG

“…1,2 With the imaging ability and ablating properties of the radioactive isotope 131 I-iodine, the 131 Iiodine-labelled MIBG is used for diagnosis and treatment of neurilemma tumors in the clinic, such as malignant neurilemmoma, neuroendocrine tumor, neuroblastoma, pheochromocytoma, paraganglioma, and thyroid medullary carcinoma. 1,2 With the imaging ability and ablating properties of the radioactive isotope 131 I-iodine, the 131 Iiodine-labelled MIBG is used for diagnosis and treatment of neurilemma tumors in the clinic, such as malignant neurilemmoma, neuroendocrine tumor, neuroblastoma, pheochromocytoma, paraganglioma, and thyroid medullary carcinoma.…”

“…MIBG (metaiodobenzylguanidine, formula: C 8 H 10 IN 3 , molecular weight: 275.1) is a kind of adrenergic neuro blocker, which is a structural analogue of the neurotransmitter norepinephrine (NE), and was taken up into cells rich in sympathetic neurons through the NE transporter. 1,2 With the imaging ability and ablating properties of the radioactive isotope 131 I-iodine, the 131 Iiodine-labelled MIBG is used for diagnosis and treatment of neurilemma tumors in the clinic, such as malignant neurilemmoma, neuroendocrine tumor, neuroblastoma, pheochromocytoma, paraganglioma, and thyroid medullary carcinoma. [3][4][5] The no-carrier-added (nca) 131 I-MIBG has attracted a lot of attentions nowadays due to the higher specific activity (SA) and lower side effect benefits compared to the clinically applied carrier-added (ca) 131 I-MIBG.…”